Efter 24 ugers behandling oplevede Naglazyme- behandlede patienter en 92 ± 40 m forbedring i den afstand, de kunne gå i løbet af 12 minutter, i forhold til patienter i placebo- gruppen (p = 0, 025).
Following 24 weeks of therapy, Naglazyme-treated patients experienced a 92 ± 40 m improvement in the distance walked in 12 minutes relative to placebo-treated patients (p = 0.025).